Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial crawled time : 12:30 save search
Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder
Published: 2024-04-10 (Crawled : 12:30) - globenewswire.com
ADIL | $1.9 -12.44% -14.21% 310K
|
Health Technology
|
| O: 123.48%
H: 0.0%
C: 0.0%
ad04 alcohol publication treatment pharmaceuticals for trial potential
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
Published: 2024-04-08 (Crawled : 12:30) - prnewswire.com
NRXP 1 d | $3.08 1.99% 1.95% 230K
|
Manufacturing
|
| O: 0.57%
H: 7.01%
C: 3.79%
nrx-101 depression treatment pharmaceuticals trial
Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research
Published: 2024-04-08 (Crawled : 12:30) - globenewswire.com
ENTX | $1.985 -11.38% -12.85% 300K
|
Health Technology
|
| O: 2.3%
H: 1.25%
C: -2.5%
eb613 publication research bone trial
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
Published: 2024-04-05 (Crawled : 12:30) - biospace.com/
NTRA S | $85.275 -2.3% -2.35% 2.5M
|
Health Services
|
| O: 2.12%
H: 4.35%
C: 2.25%
bladder positive cancer trial
eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
Published: 2024-04-04 (Crawled : 12:30) - globenewswire.com
EFTR | $1.645 -7.58% -8.21% 200K
|
|
| O: -76.55%
H: 13.89%
C: -17.78%
lung cancer cell topline trial therapeutics results
Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
Published: 2024-04-03 (Crawled : 12:30) - prnewswire.com
GNPX | $2.2194 -2.31% 38K
|
Health Technology
|
| O: 1.76%
H: 13.15%
C: 7.61%
reqorsa lung cancer treat cell trial therapy study
PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy
Published: 2024-04-02 (Crawled : 12:30) - globenewswire.com
PRFX | News 0 d | $0.8737 -1.83% -1.87% 29K
|
Health Technology
|
| O: 9.2%
H: 0.0%
C: -8.95%
prf-110 trial
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan
Published: 2024-04-01 (Crawled : 12:30) - globenewswire.com
VIRX | $0.88 -3.19% -3.3% 53K
|
Manufacturing
|
| O: 0.96%
H: 8.57%
C: 5.71%
congress topline trial therapeutics results
Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024
Published: 2024-03-26 (Crawled : 12:30) - globenewswire.com
INZY | $4.5 -1.75% -1.78% 590K
|
Health Technology
|
| O: 2.09%
H: 14.47%
C: 6.6%
inz-701 pharma report ongoing trials topline
Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer
Published: 2024-03-18 (Crawled : 12:30) - biospace.com/
NTRA S | $85.275 -2.3% -2.35% 2.5M
|
Health Services
|
| O: 0.19%
H: 1.46%
C: 0.48%
cancer trial
Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder
Published: 2024-03-15 (Crawled : 12:30) - biospace.com/
CYBN | News | $0.3677 -0.6% 0.35% 1.8M
|
n/a
|
| O: 1.59%
H: 7.78%
C: 5.55%
cyb004 study
Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design
Published: 2024-03-14 (Crawled : 12:30) - biospace.com/
CYBN | News | $0.3677 -0.6% 0.35% 1.8M
|
n/a
|
| O: 7.14%
H: 5.53%
C: -4.67%
cyb003 fda positive meeting program design
Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial
Published: 2024-03-13 (Crawled : 12:30) - globenewswire.com
CMND | $1.22 3.56% 3.43% 110K
|
n/a
|
| O: -2.72%
H: 1.4%
C: -4.9%
clearance trial
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Published: 2024-03-12 (Crawled : 12:30) - biospace.com/
RGLS | $2.13 -4.05% -4.23% 220K
|
Health Technology
|
| O: 68.84%
H: 62.66%
C: 1.29%
rgls8429 disease kidney positive treatment topline trial therapeutics
Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS® Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Published: 2024-03-12 (Crawled : 12:30) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.21%
H: 0.11%
C: -1.06%
adcetris positive trial
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting
Published: 2024-03-11 (Crawled : 12:30) - globenewswire.com
DERM | $3.45 -3.63% -3.77% 100K
|
|
| O: -1.45%
H: 0.88%
C: -0.88%
FBIO | $1.765 -2.49% -2.55% 190K
|
Health Technology
|
| O: -0.48%
H: 2.87%
C: -4.31%
dfd-29 presentation corporation meeting impact medical trial
Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma
Published: 2024-03-07 (Crawled : 12:30) - globenewswire.com
MBIO | $0.3451 -6.98% -7.51% 130K
|
Health Technology
|
| O: 8.33%
H: 4.2%
C: -2.8%
FBIO | $1.765 -2.49% -2.55% 190K
|
Health Technology
|
| O: 2.93%
H: 0.0%
C: -9.21%
mb-101 publication trial
City of Hope-developed Chimeric Antigen Receptor (CAR) T Cell Therapy Shows Clinical Activity in Patients With Aggressive Brain Tumors in a Phase 1 Trial
Published: 2024-03-07 (Crawled : 12:30) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320
|
Communications
|
| O: 0.79%
H: 0.78%
C: 0.78%
MBIO | $0.3451 -6.98% -7.51% 130K
|
Health Technology
|
| O: 8.33%
H: 4.2%
C: -2.8%
FBIO | $1.765 -2.49% -2.55% 190K
|
Health Technology
|
| O: 2.93%
H: 0.0%
C: -9.21%
tumors cell city trial therapy
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma
Published: 2024-03-06 (Crawled : 12:30) - globenewswire.com
KURA | $17.55 -0.74% -0.74% 1.3M
|
Health Technology
|
| O: 1.28%
H: 8.54%
C: 6.52%
ko-2806 first renal cell trial plus
Insulet to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
Published: 2024-03-05 (Crawled : 12:30) - biospace.com/
PODD | $166.255 0.93% 0.92% 840K
|
Health Technology
|
| O: 1.89%
H: 0.02%
C: -4.13%
omnipod first conference international trial advanced diabetes results
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.